HPP737 is a novel, potent and selective PDE4 inhibitor. In May 2018, we licensed the rights to develop and commercialize HPP737 in China and certain Pacific Rim territories to Newsoara Biopharma.
We are conducting a Multiple Ascending Dose study in healthy volunteers to determine doses for a Proof of Concept study in Psoriasis.
HPP737 has shown potent inhibition of IL23 and TNF-alpha production and therapeutic in vivo activity in several animal models of inflammation including COPD and Psoriasis. HPP737 has completed two phase 1 studies showing little or no gastrointestinal distress. Additionally, HPP737 demonstrated target engagement ex vivo. Preclinical and clinical data suggests HPP737 may not have the side effects common to other PDE4 inhibitors in development.
Mechanism of Action
Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad range of anti-inflammatory effects. However, the therapeutic potential of PDE4 inhibitors has been limited by dose limiting adverse events such as nausea and emesis.
Presentations and Posters
Links to the following publications and presentations that are located on outside websites, are provided for informational purposes only and do not constitute the opinions or views of vTv Therapeutics
Burstein A., Wang S., Clark D., Kostura M., Dunn I. Pharmacokinetics and Pharmacodynamics of the Phosphodiesterase 4 (PDE4) inhibitor HPP737 Following Single-dose Administration in Healthy Subjects. Presented at the 6th World Psoriasis and Psoriatic Arthritis Conference – Virtual, June 30, 2021.